secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2022-04-11T23:59:59+00:00
Accession:  0001213900-22-019217
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq
--------------------------------------------------------------------------------

- Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).
- Issued 36.9M Class A shares and 15.8M Class C shares; PIPE investors subscribed 11.7M Class A shares at $10.00 each, grossing ~$116M.
- Existing MoonLake AG shareholders received 18.5M Class A and 15.8M Class C shares; lock-up periods of 6 to 12 months apply.
- Helix contributed $134.6M to MoonLake AG, including $15M loan repayment to Cormorant Asset Management.
- New equity incentive plan adopted; initial grants of 45,000 options per non-management director; indemnification agreements executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-019217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer